Alzheimer’s disease

NICE Appraisals

TA217 Donepezil, galantamine rivastigmine and memantine for the treatment of Alzheimer’s disease (March 2011)

TA111  Donepezil, rivastigmine, galantamine and memantine for the treatment of Alzheimer’s disease (including a review of TA19) (March 2010)

DSU Report

A review of the Eisai / Pfizer economic model on the cost-effectiveness of donepezil (June 2010) a report contributing to the PenTAG report “The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatement of Alzheimer’s disease (review of TA111): a systematic review and economic model

Donepezil, rivatigmine, galantamine and memantine for the treatment of Alzheimer’s disease: A review of comments submitted by consultees on the reliability of economic model (March 2009) for TA111